drugset
Drugs / TLL018
last change Jul 2026 re-read 2 minutes ago

TLL018

targets JAK1, TYK2 via inhibition

Developed for
chronic idiopathic urticaria · rheumatoid arthritis · psoriasis · ulcerative colitis
Investigated by
Hangzhou Highlightll Pharmaceutical Co., Ltd · TLL Pharmaceutical, LLC

Trials 10 · a red edge is where a trial was stopped

today NCT07665996 · Ph 1/2 NCT06887127 · Ph 3 NCT06396026 · Ph 3 NCT06020144 · Ph 3 NCT05772520 · Ph 2 NCT05121402 · Ph 2 NCT05342428 · Ph 1 NCT05373355 · Ph 1 NCT05133297 · Ph 2 NCT04243083 · Ph 1
202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT05342428 Jun 2022 → Aug 2023 psoriasis Hangzhou Highlightll Pharmaceutical Co., Ltd Completed No outcome recorded
Phase 1 NCT05373355 May 2022 → Sep 2023 chronic idiopathic urticaria Hangzhou Highlightll Pharmaceutical Co., Ltd Completed No outcome recorded
Phase 1 NCT04243083 Jan → Dec 2020 — TLL Pharmaceutical, LLC Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT07665996 Jul 2026 → Dec 2027 expected chronic idiopathic urticaria Hangzhou Highlightll Pharmaceutical Co., Ltd Not yet recruiting No outcome recorded
Phase 23 trials
Phase 2 NCT05772520 Jan 2023 → Dec 2024 psoriasis Hangzhou Highlightll Pharmaceutical Co., Ltd Completed No outcome recorded
Phase 2 NCT05121402 Dec 2022 → Jul 2023 ulcerative colitis TLL Pharmaceutical, LLC Withdrawn No outcome recorded
Phase 2 NCT05133297 Feb → Dec 2022 rheumatoid arthritis Hangzhou Highlightll Pharmaceutical Co., Ltd Completed No outcome recorded
Phase 33 trials
Phase 3 NCT06887127 Mar 2025 → Dec 2026 expected rheumatoid arthritis Hangzhou Highlightll Pharmaceutical Co., Ltd Recruiting No outcome recorded
Phase 3 NCT06396026 Mar 2024 → Oct 2025 overdue chronic idiopathic urticaria Hangzhou Highlightll Pharmaceutical Co., Ltd Active not recruiting No outcome recorded
Phase 3 NCT06020144 Nov 2023 → Jan 2026 overdue rheumatoid arthritis Hangzhou Highlightll Pharmaceutical Co., Ltd Active not recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as TLL018 “TLL018 tablets,1 tablet ,BID” NCT06396026 ↗
10

NCT06887127 ↗

NCT05342428 ↗

NCT05121402 ↗

NCT07665996 ↗

NCT05373355 ↗

NCT06396026 ↗

NCT05772520 ↗

NCT04243083 ↗

NCT05133297 ↗

NCT06020144 ↗
Action Inhibit “a TYK2/JAK1 inhibitor” NCT05121402 ↗
Route Oral “Oral QD” NCT04243083 ↗
Target JAK1 “a TYK2/JAK1 inhibitor” NCT05121402 ↗
Target TYK2 “a TYK2/JAK1 inhibitor” NCT05121402 ↗